Shionogi & Co

Shionogi & Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Shionogi & Co (4507.T) as of Oct 15, 2026 is 161.38 B JPY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 168.77 B JPY — a change of -4.38% (lower).

EBITDA

161.38 BJPY

YoY

-4.38%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Shionogi & Co is 2026 161.38 B JPY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Shionogi & Co was 2025 168.77 B JPY. It decreases by -4.38% lower compared to the previous year.

The Shionogi & Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
145.19 B JPY
Jan 1, 2020
136.84 B JPY
Jan 1, 2021
102.02 B JPY
Jan 1, 2022
118.85 B JPY
Jan 1, 2023
168.41 B JPY
Jan 1, 2024
179.85 B JPY
Jan 1, 2025
168.77 B JPY
Jan 1, 2026
161.38 B JPY
The Shionogi & Co EBITDA history
YEAREBITDAYoY
161.38 BJPY-4.38%
168.77 BJPY-6.16%
179.85 BJPY+6.80%
168.41 BJPY+41.70%
118.85 BJPY+16.50%
102.02 BJPY-25.45%
136.84 BJPY-5.75%
145.19 BJPY+26.01%
115.22 BJPY+6.51%
108.18 BJPY+18.35%
91.41 BJPY+81.49%
50.37 BJPY-20.75%
63.56 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shionogi & Co Stock analysis

What does Shionogi & Co do? The company Shionogi & Co Ltd is a Japanese pharmaceutical company based in Osaka. It was founded in 1878 and has since become a significant player in the industry. It currently employs over 6,000 employees worldwide and is listed on the Tokyo Stock Exchange. Shionogi is divided into several business segments that offer different products and services. The largest segment is the pharmaceutical division, which specializes in the development and marketing of drugs. The company has strong expertise in infectious diseases, pain management, and oncology, and operates in many countries worldwide. One flagship product is the antibiotic Cefditoren, used to treat various bacterial infections. In addition to the pharmaceutical division, Shionogi is also active in other areas. For example, the company offers diagnostic and laboratory services, operating multiple labs in Japan and other countries. Another business segment is the production and marketing of nutritional supplements, sold in Japan, China, and the USA. Shionogi's business model is based on extensive research and development, as well as strong brand positioning. The company invests a significant portion of its revenue each year in the research and development of new drugs and better treatment options for existing diseases. Thanks to the high quality of its products and strong brand, the company has a loyal customer base. In recent years, Shionogi has focused on international expansion opportunities and has expanded its activities in various regions. For example, it has partnered with US pharmaceutical company Purdue Pharma to develop and market a novel pain medication. Shionogi's annual revenue is around 1.5 billion euros. The company is particularly strong in Japan and other Asian countries, but is also active in the US and Europe. In the coming years, Shionogi aims to further expand its international business and solidify its position as a significant player in the industry. Key focuses will be on the launch of new products and finding treatments for previously incurable diseases. Overall, Shionogi is an innovative and successful company that utilizes its expertise in the pharmaceutical industry in various ways. With its dedicated employees and strong brand, it will continue to play an important role in the industry. Shionogi & Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shionogi & Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Shionogi & Co is 161.38 B JPY in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Shionogi & Co changed from 168.77 B JPY to 161.38 B JPY, representing a -4.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Shionogi & Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Shionogi & Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Shionogi & Co

All Key Metrics — Shionogi & Co